BYBEE CLINTON — SEC insider filings
SEC reporting owner CIK 1219043. 38 insider filings on record with FilingPulse; latest filed 2026-11-05.
Transaction summary — filings shown
Covers all 38 filings on record, filed 2020-09-22 to 2026-11-05. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 14 legs across 10 filings — 14,008,233 shares, $101,214,949 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 1 leg across 1 filing — 16,000 shares, $39,840 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 213.
- Largest priced transaction: purchase of 1,500,000 shares @ $17.00 ($25,500,000) in Neumora Therapeutics, Inc., filed 2023-09-20.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | 10% owner | 4 | 2 legs · 2,809,352 sh · $37,499,977 | — | 6 |
| Neumora Therapeutics, Inc. (NMRA) | 10% owner | 3 | 2 legs · 3,415,700 sh · $30,499,977 | — | 12 |
| Codiak BioSciences, Inc. (CDAK) | 10% owner | 2 | 2 legs · 5,235,000 sh · $11,025,000 | — | 11 |
| Sana Biotechnology, Inc. (SANA) | 10% owner | 2 | 3 legs · 1,818,181 sh · $9,999,996 | — | 14 |
| 908 Devices Inc. (MASS) | 10% owner | 1 | 1 leg · 300,000 sh · $6,000,000 | — | 6 |
| Boundless Bio, Inc. (BOLD) | 10% owner | 2 | 2 legs · 200,000 sh · $3,200,000 | 1 leg · 16,000 sh · $39,840 | 12 |
| Metacrine, Inc. (MTCR) | 10% owner | 1 | 2 legs · 230,000 sh · $2,990,000 | — | 8 |
| Vir Biotechnology, Inc. (VIR) | 10% owner | 14 | — | — | 95 |
| Beam Therapeutics Inc. (BEAM) | 10% owner | 4 | — | — | 27 |
| Karuna Therapeutics, Inc. (KRTX) | 10% owner | 3 | — | — | 12 |
+2 more issuers among the filings shown — every filing appears in the table below.
Insider filings — BYBEE CLINTON
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-05 | 4 | Lyell Immunopharma, Inc. (LYEL) jointly with ARCH Venture Fund XIII, L.P., ARCH Venture Partners XIII, L.P., ARCH Venture Partners XIII, LLC, CRANDELL KEITH, GILLIS STEVEN, NELSEN ROBERT, Burow Kristina, BERNS PAUL L | Purchase (P): 2,321,262 @ $10.77 | EDGAR |
| 2026-07-06 | 4 | Boundless Bio, Inc. (BOLD) jointly with CRANDELL KEITH, NELSEN ROBERT, GILLIS STEVEN, Burow Kristina | Option exercise (M): 16,000 @ $1.03 · Sale (S): 16,000 @ $2.49 · Option exercise (M): 16,000 (derivative) @ $0 | EDGAR |
| 2026-03-09 | 4 | Lyell Immunopharma, Inc. (LYEL) jointly with ARCH Venture Fund XIII, L.P., ARCH Venture Partners XIII, L.P., ARCH Venture Partners XIII, LLC, CRANDELL KEITH, NELSEN ROBERT, Burow Kristina, GILLIS STEVEN, BERNS PAUL L | Purchase (P): 488,090 @ $25.61 | EDGAR |
| 2025-10-29 | 4 | Neumora Therapeutics, Inc. (NMRA) jointly with ARCH Venture Partners XII, LLC, ARCH Venture Partners XII, L.P., ARCH Venture Fund XII, L.P., CRANDELL KEITH, GILLIS STEVEN, NELSEN ROBERT | Purchase (P): 1,915,700 @ $2.61 | EDGAR |
| 2025-07-29 | 4 | Lyell Immunopharma, Inc. (LYEL) jointly with ARCH Venture Partners IX, LLC, ARCH Venture Partners IX, L.P., ARCH Venture Partners IX Overage, L.P., ARCH Venture Fund IX, L.P., ARCH Venture Fund IX Overage, L.P., CRANDELL KEITH, NELSEN ROBERT | Holdings only — no transactions reported | EDGAR |
| 2024-04-04 | 4 | Boundless Bio, Inc. (BOLD) jointly with CRANDELL KEITH, NELSEN ROBERT, GILLIS STEVEN | Conversion (C): 589,743 · Conversion (C): 787,545 · Conversion (C): 1,048,433 · Purchase (P): 66,667 @ $16 · Purchase (P): 133,333 @ $16 · Conversion (C): 424,908 (derivative) · +6 more | EDGAR |
| 2024-02-12 | 4 | Sana Biotechnology, Inc. (SANA) jointly with CRANDELL KEITH, Burow Kristina, GILLIS STEVEN | Purchase (P): 363,637 @ $5.50 · Purchase (P): 727,272 @ $5.50 · Purchase (P): 727,272 @ $5.50 | EDGAR |
| 2023-12-12 | 4 | Neumora Therapeutics, Inc. (NMRA) jointly with ARCH Venture Partners XII, LLC, ARCH Venture Partners XII, L.P., ARCH Venture Fund XII, L.P., CRANDELL KEITH, GILLIS STEVEN, NELSEN ROBERT | Other (J): 703,061 · Other (J): 1,176,593 | EDGAR |
| 2023-09-20 | 4 | Neumora Therapeutics, Inc. (NMRA) jointly with ARCH Venture Partners X, LLC, ARCH Venture Partners XII, LLC, ARCH Venture Partners XII, L.P., ARCH Venture Fund XII, L.P., CRANDELL KEITH, GILLIS STEVEN, NELSEN ROBERT | Conversion (C): 684,167 · Conversion (C): 1,144,973 · Conversion (C): 6,895,021 · Conversion (C): 6,576,400 · Conversion (C): 2,124,143 · Purchase (P): 1,500,000 @ $17 · +5 more | EDGAR |
| 2022-09-15 | 4 | Codiak BioSciences, Inc. (CDAK) jointly with ARCH Venture Fund VIII, L.P., ARCH Venture Fund VIII Overage, L.P., CRANDELL KEITH, NELSEN ROBERT, ARCH Venture Partners VIII, LLC, ARCH Venture Partners VIII, L.P. | Purchase (P): 5,000,000 @ $1.50 · Purchase (P): 5,000,000 (derivative) | EDGAR |
| 2022-09-07 | 4 | Vir Biotechnology, Inc. (VIR) jointly with ARCH Venture Partners IX, LLC, ARCH Venture Partners IX, L.P., ARCH Venture Partners IX Overage, L.P., ARCH Venture Fund IX, L.P., ARCH Venture Fund IX Overage, L.P., CRANDELL KEITH | Other (J): 196,003 @ $0 · Other (J): 253,997 @ $0 · Other (J): 11,763 @ $0 · Other (J): 1,338 @ $0 · Other (J): 2,662 @ $0 · Other (J): 239,559 @ $0 · +4 more | EDGAR |
| 2022-09-01 | 4 | Vir Biotechnology, Inc. (VIR) jointly with ARCH Venture Partners IX, LLC, ARCH Venture Partners IX, L.P., ARCH Venture Partners IX Overage, L.P., ARCH Venture Fund IX, L.P., ARCH Venture Fund IX Overage, L.P., CRANDELL KEITH | Other (J): 217,781 @ $0 · Other (J): 282,219 @ $0 · Other (J): 13,076 @ $0 · Other (J): 1,475 @ $0 · Other (J): 2,952 @ $0 · Other (J): 217,781 @ $0 · +4 more | EDGAR |
| 2022-08-26 | 4 | Vir Biotechnology, Inc. (VIR) jointly with ARCH Venture Partners IX, LLC, ARCH Venture Partners IX, L.P., ARCH Venture Partners IX Overage, L.P., ARCH Venture Fund IX, L.P., ARCH Venture Fund IX Overage, L.P., CRANDELL KEITH | Other (J): 217,781 @ $0 · Other (J): 282,219 @ $0 · Other (J): 13,076 @ $0 · Other (J): 1,475 @ $0 · Other (J): 2,952 @ $0 · Other (J): 217,781 @ $0 · +4 more | EDGAR |
| 2022-08-22 | 4 | Vir Biotechnology, Inc. (VIR) jointly with ARCH Venture Partners IX, LLC, ARCH Venture Partners IX, L.P., ARCH Venture Partners IX Overage, L.P., ARCH Venture Fund IX, L.P., ARCH Venture Fund IX Overage, L.P., CRANDELL KEITH | Other (J): 217,781 @ $0 · Other (J): 282,219 @ $0 · Other (J): 13,076 @ $0 · Other (J): 1,475 @ $0 · Other (J): 2,952 @ $0 | EDGAR |
| 2022-08-16 | 4 | Vir Biotechnology, Inc. (VIR) jointly with ARCH Venture Partners IX, LLC, ARCH Venture Partners IX, L.P., ARCH Venture Partners IX Overage, L.P., ARCH Venture Fund IX, L.P., ARCH Venture Fund IX Overage, L.P., CRANDELL KEITH | Other (J): 217,781 @ $0 · Other (J): 282,219 @ $0 · Other (J): 13,076 @ $0 · Other (J): 1,475 @ $0 · Other (J): 2,952 @ $0 · Other (J): 217,781 @ $0 · +9 more | EDGAR |
| 2022-06-10 | 4 | Vir Biotechnology, Inc. (VIR) jointly with ARCH Venture Partners IX, LLC, ARCH Venture Partners IX, L.P., ARCH Venture Partners IX Overage, L.P., ARCH Venture Fund IX, L.P., ARCH Venture Fund IX Overage, L.P., CRANDELL KEITH | Other (J): 217,781 @ $0 · Other (J): 282,219 @ $0 · Other (J): 13,076 @ $0 · Other (J): 1,475 @ $0 · Other (J): 2,952 @ $0 | EDGAR |
| 2022-06-06 | 4 | Vir Biotechnology, Inc. (VIR) jointly with ARCH Venture Partners IX, LLC, ARCH Venture Partners IX, L.P., ARCH Venture Partners IX Overage, L.P., ARCH Venture Fund IX, L.P., ARCH Venture Fund IX Overage, L.P., CRANDELL KEITH | Other (J): 217,781 @ $0 · Other (J): 282,219 @ $0 · Other (J): 13,076 @ $0 · Other (J): 4,426 @ $0 | EDGAR |
| 2021-12-22 | 4 | Vir Biotechnology, Inc. (VIR) jointly with ARCH Venture Partners IX, LLC, ARCH Venture Partners IX, L.P., ARCH Venture Partners IX Overage, L.P., ARCH Venture Fund IX, L.P., ARCH Venture Fund IX Overage, L.P., CRANDELL KEITH | Other (J): 762,233 @ $0 · Other (J): 987,767 @ $0 · Other (J): 45,703 @ $0 · Other (J): 15,504 @ $0 | EDGAR |
| 2021-12-01 | 4 | Vir Biotechnology, Inc. (VIR) jointly with ARCH Venture Partners IX, LLC, ARCH Venture Partners IX, L.P., ARCH Venture Partners IX Overage, L.P., ARCH Venture Fund IX, L.P., ARCH Venture Fund IX Overage, L.P., CRANDELL KEITH | Other (J): 217,781 @ $0 · Other (J): 282,219 @ $0 · Other (J): 13,057 @ $0 · Other (J): 4,428 @ $0 | EDGAR |
| 2021-11-24 | 4 | Vir Biotechnology, Inc. (VIR) jointly with ARCH Venture Partners IX, LLC, ARCH Venture Partners IX, L.P., ARCH Venture Partners IX Overage, L.P., ARCH Venture Fund IX, L.P., ARCH Venture Fund IX Overage, L.P., CRANDELL KEITH | Other (J): 217,781 @ $0 · Other (J): 282,219 @ $0 · Other (J): 13,057 @ $0 · Other (J): 4,428 @ $0 | EDGAR |
| 2021-07-06 | 4 | Vir Biotechnology, Inc. (VIR) jointly with ARCH Venture Partners IX, LLC, ARCH Venture Partners IX, L.P., ARCH Venture Partners IX Overage, L.P., ARCH Venture Fund IX, L.P., ARCH Venture Fund IX Overage, L.P., CRANDELL KEITH | Other (J): 1,742,248 @ $0 · Other (J): 2,257,752 @ $0 · Other (J): 25,279 @ $0 · Other (J): 8,133 @ $0 | EDGAR |
| 2021-07-02 | 4 | Beam Therapeutics Inc. (BEAM) jointly with ARCH Venture Partners IX, LLC, ARCH Venture Partners IX, L.P., ARCH Venture Partners IX Overage, L.P., ARCH Venture Fund IX, L.P., ARCH Venture Fund IX Overage, L.P., CRANDELL KEITH, NELSEN ROBERT | Other (J): 200,000 @ $0 · Other (J): 200,000 @ $0 · Other (J): 2,555 @ $0 · Other (J): 811 @ $0 · Other (J): 4,686 @ $0 | EDGAR |
| 2021-06-29 | 4 | Beam Therapeutics Inc. (BEAM) jointly with ARCH Venture Partners IX, LLC, ARCH Venture Partners IX, L.P., ARCH Venture Partners IX Overage, L.P., ARCH Venture Fund IX, L.P., ARCH Venture Fund IX Overage, L.P., CRANDELL KEITH, NELSEN ROBERT | Other (J): 200,000 @ $0 · Other (J): 200,000 @ $0 · Other (J): 2,555 @ $0 · Other (J): 811 @ $0 · Other (J): 4,686 @ $0 · Other (J): 200,000 @ $0 · +4 more | EDGAR |
| 2021-06-24 | 4 | Vir Biotechnology, Inc. (VIR) jointly with ARCH Venture Partners IX, LLC, ARCH Venture Partners IX, L.P., ARCH Venture Partners IX Overage, L.P., ARCH Venture Fund IX, L.P., ARCH Venture Fund IX Overage, L.P., CRANDELL KEITH | Other (J): 435,562 @ $0 · Other (J): 564,438 @ $0 · Other (J): 6,320 @ $0 · Other (J): 2,028 @ $0 | EDGAR |
| 2021-06-23 | 4 | Lyell Immunopharma, Inc. (LYEL) jointly with ARCH Venture Partners IX, LLC, ARCH Venture Fund IX Overage, L.P., ARCH Venture Fund IX, L.P., ARCH Venture Partners IX Overage, L.P., ARCH Venture Partners IX, L.P., CRANDELL KEITH | Conversion (C): 18,206,358 · Conversion (C): 18,206,358 · Conversion (C): 17,771,216 (derivative) @ $0 · Conversion (C): 17,771,216 (derivative) @ $0 · Conversion (C): 435,142 (derivative) @ $0 · Conversion (C): 435,142 (derivative) @ $0 | EDGAR |
| 2021-04-15 | 4 | Karuna Therapeutics, Inc. (KRTX) jointly with ARCH Venture Partners IX, LLC, ARCH Venture Partners IX, L.P., ARCH Venture Partners IX Overage, L.P., ARCH Venture Fund IX, L.P., ARCH Venture Fund IX Overage, L.P., CRANDELL KEITH | Other (J): 75,000 @ $0 · Other (J): 75,000 @ $0 · Other (J): 958 @ $0 · Other (J): 306 @ $0 | EDGAR |
| 2021-04-09 | 4 | Vir Biotechnology, Inc. (VIR) jointly with ARCH Venture Partners IX, LLC, ARCH Venture Partners IX, L.P., ARCH Venture Partners IX Overage, L.P., ARCH Venture Fund IX, L.P., ARCH Venture Fund IX Overage, L.P., CRANDELL KEITH | Other (J): 217,781 @ $0 · Other (J): 282,219 @ $0 · Other (J): 3,161 @ $0 · Other (J): 1,019 @ $0 · Other (J): 217,781 @ $0 · Other (J): 282,219 @ $0 · +2 more | EDGAR |
| 2021-04-02 | 4 | Beam Therapeutics Inc. (BEAM) jointly with ARCH Venture Partners IX, LLC, ARCH Venture Partners IX, L.P., ARCH Venture Partners IX Overage, L.P., ARCH Venture Fund IX, L.P., ARCH Venture Fund IX Overage, L.P., CRANDELL KEITH | Other (J): 200,000 @ $0 · Other (J): 200,000 @ $0 · Other (J): 2,555 @ $0 · Other (J): 811 @ $0 | EDGAR |
| 2021-04-01 | 4 | Vir Biotechnology, Inc. (VIR) jointly with ARCH Venture Partners IX, LLC, ARCH Venture Partners IX, L.P., ARCH Venture Partners IX Overage, L.P., ARCH Venture Fund IX, L.P., ARCH Venture Fund IX Overage, L.P., CRANDELL KEITH | Other (J): 217,781 @ $0 · Other (J): 282,219 @ $0 · Other (J): 3,160 @ $0 · Other (J): 1,014 @ $0 · Other (J): 217,781 @ $0 · Other (J): 282,219 @ $0 · +2 more | EDGAR |
| 2021-03-22 | 4 | Beam Therapeutics Inc. (BEAM) jointly with ARCH Venture Partners IX, LLC, ARCH Venture Partners IX, L.P., ARCH Venture Partners IX Overage, L.P., ARCH Venture Fund IX, L.P., ARCH Venture Fund IX Overage, L.P., CRANDELL KEITH | Other (J): 200,000 @ $0 · Other (J): 200,000 @ $0 · Other (J): 2,553 @ $0 · Other (J): 810 @ $0 · Other (J): 200,000 @ $0 · Other (J): 200,000 @ $0 · +2 more | EDGAR |
| 2021-02-10 | 4 | Sana Biotechnology, Inc. (SANA) jointly with ARCH Venture Fund X, L.P., CRANDELL KEITH, Burow Kristina, GILLIS STEVEN | Conversion (C): 10,156,250 · Conversion (C): 10,156,250 · Conversion (C): 11,718,750 · Conversion (C): 11,718,750 · Conversion (C): 3,687,500 (derivative) @ $0 · Conversion (C): 3,687,500 (derivative) @ $0 · +8 more | EDGAR |
| 2021-01-12 | 4 | Karuna Therapeutics, Inc. (KRTX) jointly with ARCH Venture Partners IX, LLC, ARCH Venture Partners IX, L.P., ARCH Venture Partners IX Overage, L.P., ARCH Venture Fund IX, L.P., ARCH Venture Fund IX Overage, L.P., CRANDELL KEITH | Other (J): 75,000 @ $0 · Other (J): 75,000 @ $0 · Other (J): 958 @ $0 · Other (J): 306 @ $0 | EDGAR |
| 2020-12-22 | 4 | 908 Devices Inc. (MASS) jointly with ARCH Venture Fund VII, L.P., ARCH Venture Partners VII, L.P., ARCH Venture Partners VII, LLC, NELSEN ROBERT | Conversion (C): 5,425,045 · Purchase (P): 300,000 @ $20 · Conversion (C): 2,927,386 (derivative) @ $0 · Conversion (C): 981,443 (derivative) @ $0 · Conversion (C): 669,977 (derivative) @ $0 · Conversion (C): 665,661 (derivative) @ $0 · +1 more | EDGAR |
| 2020-11-24 | 4 | Quanterix Corp (QTRX) jointly with ARCH VENTURE FUND VI LP, ARCH Venture Fund VIII Overage, L.P., ARCH VENTURE PARTNERS VI LP, ARCH VENTURE PARTNERS VI LLC, ARCH Venture Partners VIII, LLC, NELSEN ROBERT | Other (J): 229,006 @ $0 · Other (J): 145,994 @ $0 · Other (J): 854 @ $0 · Other (J): 853 @ $0 · Other (J): 277,514 @ $0 · Other (J): 176,920 @ $0 · +2 more | EDGAR |
| 2020-11-16 | 4 | Karuna Therapeutics, Inc. (KRTX) jointly with ARCH Venture Partners IX, LLC, ARCH Venture Partners IX, L.P., ARCH Venture Partners IX Overage, L.P., ARCH Venture Fund IX, L.P., ARCH Venture Fund IX Overage, L.P., CRANDELL KEITH | Other (J): 75,000 @ $0 · Other (J): 75,000 @ $0 · Other (J): 958 @ $0 · Other (J): 306 @ $0 | EDGAR |
| 2020-10-23 | 4 | IMPINJ INC (PI) | Option exercise (M): 3,411 @ $0 · Option exercise (M): 3,411 (derivative) @ $0 | EDGAR |
| 2020-10-20 | 4 | Codiak BioSciences, Inc. (CDAK) jointly with ARCH Venture Fund VIII, L.P., ARCH Venture Fund VIII Overage, L.P., CRANDELL KEITH, NELSEN ROBERT, ARCH Venture Partners VIII, LLC, ARCH Venture Partners VIII, L.P. | Conversion (C): 1,784,572 · Conversion (C): 831,521 · Conversion (C): 420,368 · Conversion (C): 326,953 · Conversion (C): 191,721 · Purchase (P): 235,000 @ $15 · +5 more | EDGAR |
| 2020-09-22 | 4 | Metacrine, Inc. (MTCR) jointly with ARCH Venture Fund VIII, L.P., ARCH Venture Fund VIII Overage, L.P., CRANDELL KEITH, NELSEN ROBERT, ARCH Venture Partners VIII, LLC, ARCH Venture Partners VIII, L.P. | Conversion (C): 1,960,784 · Conversion (C): 472,251 · Conversion (C): 138,734 · Purchase (P): 210,000 @ $13 · Conversion (C): 138,734 · Purchase (P): 20,000 @ $13 · +4 more | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-09-21 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1219043 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs